Search

Essential oils (EOs) comprised of various bioactive compounds have been widely detected in the Curcuma species. Due to the widespread distribution and misidentification of Curcuma species and differences in processing methods, inconsistent reports on major compounds in rhizomes of the same species from different geographical regions are not uncommon. This inconsistency leads to confusion and inaccuracy in compound detection of each species and also hinders comparative study based on EO compositions. The present study aimed to characterize EO compositions of 12 Curcuma species, as well as to detect the compositional variation among different species, and between the plant specimens and their related genetically validated crude drug samples using headspace solid-phase microextraction coupled with gas chromatography-mass spectrometry. The plant specimens of the same species showed similar EO patterns, regardless of introducing from different geographical sources. Based on the similarity of EO compositions, all the specimens and samples were separated into eight main groups: C. longa; C. phaeocaulis, C. aeruginosa and C. zedoaria; C. zanthorrhiza; C. aromatica and C. wenyujin; C. kwangsiensis; C. amada and C. mangga; C. petiolata; C. comosa. From EOs of all the specimens and samples, 54 major compounds were identified, and the eight groups were chemically characterized. Most of the major compounds detected in plant specimens were also observed in crude drug samples, although a few compounds converted or degraded due to processing procedures or over time. Orthogonal partial least squares-discriminant analysis allowed the marker compounds to discriminate each group or each species to be identified., (© 2022. The Author(s) under exclusive licence to The Japanese Society of Pharmacognosy.)

On 5 September 2018 the UICC-Asia Regional Office(UICC-ARO)convened the second Japan Public-Private Dialogue Forum at the House of Councilors Members' Building as a follow-up to the previous meeting held at United Nations University in Tokyo in April 2018. Senior representatives of government, academia and industry met to discuss the progress made since April, noting the significance of the Japanese government having included specific reference to cancer in its revised basic policy on the Asia Health and Wellbeing Initiative, which was adopted in July 2018. The meeting provided an opportunity for all stakeholders to discuss ways forward for improving access to cancer care, with the WHO Cancer Report and other global initiatives in mind.

Various Curcuma rhizomes have been used as medicines or spices in Asia since ancient times. It is very difficult to distinguish them morphologically, especially when they are boiled and dried, which causes misidentification leading to a loss of efficacy. We developed a method for discriminating Curcuma species by intron length polymorphism markers in genes encoding diketide-CoA synthase and curcumin synthase. This method could apply to identification of not only fresh plants but also samples of crude drugs or edible spices. By applying this method to Curcuma specimens and samples, and constructing a dendrogram based on these markers, seven Curcuma species were clearly distinguishable. Moreover, Curcuma longa specimens were geographically distinguishable. On the other hand, Curcuma kwangsiensis (gl type) specimens also showed intraspecies polymorphism, which may have occurred as a result of hybridization with other Curcuma species. The molecular method we developed is a potential tool for global classification of the genus Curcuma., (Copyright © 2015 Elsevier Ltd. All rights reserved.)

Developing and emerging countries, including China and India, account for a large proportion of the global population, and as measures to address infectious diseases in these countries bear results, we are seeing a transformation in the nature of diseases that affect these countries. It is against this backdrop that cancer is presenting an increasingly serious threat in developing countries (WHO. The World Health Report 2008--primary health care: now more than ever.) 'Global health' has become an often-heard term in discussions on international health, and backed by a number of well-funded global initiatives, it is now positioned as one of the major agenda items for the international community (Reich MR, Takemi K, Roberts MJ, Hsiao WC. Global Action on Health Systems: A Proposal for the Toyako G8 Summit. Lancet 2008;371:865-9). However, cancer has not yet attained its rightful position on this global health agenda. This paper gives an overview of the discussions that took place at the 5(th) Asia Cancer Forum. Based on the challenges and outlook for placing cancer on the global health agenda, we conduct analysis that focuses on top-down mechanisms and bottom-up mechanisms.

The Asia Cancer Forum is a body that is committed to strategic analysis in the area of cancer research. The ultimate objective of the Forum is to achieve the inclusion of cancer in the Millennium Development Goals (MDGs) of the United Nations. The MDGs have a tremendous influence on the setting of the global health agenda and the inclusion of cancer within their scope would be greatly beneficial to the global development of cancer research. Although diseases such as HIV/AIDS and malaria remain priority issues for global health, the time has come for policy transformation. Preventive activities and measures require a long period of time before results become apparent and as the cost-benefit effect of allocated funds cannot be measured in the short-term, preventive activities have therefore tended to be given a low priority in terms of national policy. We must take a long-term perspective that looks ahead to the issues that will face future generations. Transcending challenges presented by cultural diversity, we must work to position cancer as a central theme on the global health agenda, even in the face of limited medical resources. Promoting cancer prevention activities through readily available infrastructure in the form of health classes in schools is also of great significance in terms of setting the agenda for global health. As a joint China-Japan research project, in China a questionnaire survey has been implemented through school pupils, with pupils and parents being asked about health classes implemented in schools. From the perspective of formulating strategy for establishing cancer on the global health agenda we will use the data gained from the surveys to analyze and examine the possibilities and significance of creating an infrastructure for a multilateral information network about cancer prevention.

It would be a great mistake to analyze the health situation in Asia relying on the focus on individualism inherent in the sense of values of Europeans and Americans. Cooperation across fields is indispensable for effective control of the epidemic of disease we are facing in the 21st century. We need to concentrate efforts on bringing together specialists, not only within the various areas of medical practice, but also across such fields as economics, politics and information technology (IT). Asia differs from Europe and America in that it does not have any group political structure and therefore we must rely on voluntary integration of our efforts if we are to achieve the most effective application of our combined resources. Non-intervention in internal affairs is naturally a very important condition for success. Sharing of information while abiding by national regulations regarding medical data confidentiality does pose difficulties, but gentle persuasion to standardize processes with a shared commitment to overcoming problems should reduce opposition. Our common purpose in maintaining healthy societies, whether we be scientists, medical staff, economists, computer specialists or politicians, provides the bond. Ways and means by which this bond can be strengthened deserve our attention.

The Asian countries with their own particular cultural background and risk factors differ from the Western world regarding their disease burden, including the incidences of different cancers. The lack of awareness and effective screening programs in many parts of Asia means that the stage at presentation with a neoplasm is often more advanced than is typical elsewhere, with all the inherent associated problems in cancer control. In addition, the presence of racial variation in genetic polymorphisms may mean that different populations in Asia may not respond to chemotherapy or other treatment modalities in the same way as their counterparts in Europe or the United States. Therefore it is essential that research be conducted into the clinical epidemiology of efficacy of drug protocols in Asian groups, with an appropriate focus on influencing factors.